Familial adenomatous polyposis (FAP) provides a model for sporadic colorectal cancer
development. Cyclooxygenase (COX) inhibition may ameliorate polyp development, but …

Familial adenomatous polyposis (FAP) represents the setting for less than 1% of colorectal
cancers, yet has provided invaluable information regarding the molecular evolution of this …

Background: The cyclooxygenase (COX) enzymes exist in two related but unique isoforms
(COX-1 and COX-2) and catalyze the formation of prostaglandins (PGs). COX-1 is …

Background: Colorectal cancers arising in patients with familial adenomatous polyposis
(FAP) can be largely prevented by polyp surveillance and prophylactic colectomy. As a …

TEROLOGY documenting increased expression of COX-2 in colorectal cancers, without
changes in COX-1 levels when comparing normal matched colonic tissue with colorectal …

The use of NSAIDs (non-steroidal anti-inflammatory drugs) has been shown to reduce risk of
mortality from colorectal cancer. It is not known how NSAIDs inhibit the growth of colorectal …

OBJECTIVE: To describe the role of celecoxib as adjunctive therapy in the treatment of
familial adenomatous polyposis (FAP), an inherited autosomal dominant predisposition …

Increasing evidence indicates that Non-steroidal anti-inflammatory drugs (NSAIDs),
compounds that inhibit the enzymatic activity of cyclooxygenase (COX), can reduce the …

COX-2 Other mutations eg–Ras, p53 Gut factors APC mutation many different non-steroidal
anti-inflammatory drugs results in a marked decrease in tumour multiplicity. 8 Together, all …

Cyclooxygenase (COX), a key enzyme in the prostanoid biosynthetic pathway, has received
considerable attention due to its role in human cancers. Observational and randomized …